BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1352 related articles for article (PubMed ID: 33158436)

  • 1. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
    Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
    J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
    Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
    Birkeland KI; Bodegard J; Banerjee A; Kim DJ; Norhammar A; Eriksson JW; Thuresson M; Okami S; Ha KH; Kossack N; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
    Diabetes Obes Metab; 2021 Jan; 23(1):75-85. PubMed ID: 32893440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
    Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
    Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
    J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.